K Gao, R Wang, J Chen, L Cheng, J Frishcosy… - Chemical …, 2022 - ACS Publications
Despite tremendous efforts in the past two years, our understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), virus–host interactions, immune …
SARS-CoV-2 proteases Mpro and PLpro are promising targets for antiviral drug development. In this study, we present an antiviral screening strategy involving a novel in …
Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses …
S Saifi, V Ravi, S Sharma, A Swaminathan… - Genomics, 2022 - Elsevier
The global COVID-19 pandemic continues due to emerging Severe Acute Respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC). Here, we performed …
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)- coronavirus disease 2019 (COVID-19) has raised a severe global public health issue and …
A Frediansyah - Clinical Epidemiology and Global Health, 2021 - Elsevier
Objective There is no specific antiviral treatment available for coronavirus disease 2019 (COVID-19). Among the possible natural constituents is carrageenan, a polymer derived …
Severe acute respiratory syndrome 2019-new coronavirus (SARS-CoV-2) is a major global challenge caused by a pandemic disease, named 'COVID-19'with no effective and selective …
BA Comunale, RJ Larson, E Jackson-Ward, A Singh… - Viruses, 2023 - mdpi.com
Background: As long as COVID-19 endures, viral surface proteins will keep changing and new viral strains will emerge, rendering prior vaccines and treatments decreasingly effective …
X Li, L Zhang, S Chen, H Ouyang, L Ren - Microorganisms, 2021 - mdpi.com
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which caused Coronaviruses Disease 2019 (COVID-19) and a worldwide pandemic, is the seventh human …